



**Interim report
first half of 2024**

**20
24**

Prostatype Genomics AB

A decorative background image showing a microscopic view of several cells. The cells are rendered in a light blue, semi-transparent style against a dark blue background. Some cells are large and spherical with a textured surface, while others are smaller and more rounded. The overall effect is a scientific and biological theme.

Summary

First half of 2024

1 January – 30 June 2024

- Net sales amounted to 115 TSEK (447)
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -18,437 TSEK (-19,575)
- Cash flow from current operations amounted to -23,211 TSEK (-19,200)
- Total cash flow for the period amounted to -935 TSEK (476)
- Earnings per share amounted to -0.02 SEK (-0.17)



Significant events during the second half of 2023

Commercial breakthrough in the United States

In mid-May, Prostatype Genomics was able to announce that the genetic test Prostatype® is now commercially available in the United States, and the company thus achieved its most important commercial milestone to date. In addition, Prostatype® has already started to be used clinically on the first patients. Ahead of the expected Medicare approval towards the end of 2024, the company is now working intensively to get more urologists, groups of urologists and urology centres to start using Prostatype® in their clinical practice.

Professor E. David Crawford, MD, an internationally recognized expert in the prostate cancer field, became the first urologist in the United States with access to the Prostatype® testing service for clinical use, as well as the company's first customer in the United States. The collaboration with Professor Crawford is a strategic step in the preparations for a nationwide launch, and it is expected to help meet the expectations of American urologists when the Prostatype® test for patients with prostate cancer is launched broadly in the United States.

During the last year, the company's strategy to reach the US market was a key focus, including a long process with preparations, development and market penetration. In February, Prostatype was able to announce three major regulatory milestones towards entering the US market: a CLIA laboratory agreement with ResearchDx, acquisition of a CLIA Certificate, and CAP laboratory accreditation.

ResearchDx, based in Irvine, California, USA, will perform testing of Prostatype® for the US market. The agreement constitutes an important step towards being able to launch Prostatype® as a so-called LDT product (Laboratory Developed Test) in the US market.

By holding its own CLIA certificate, the company will be able to receive reimbursement payments directly from Medicare and commercial payers. This increases the company's potential revenue and profit margin in the United States compared to previously discussed options for gaining access to the US market, such as entering into a license agreement with a CLIA laboratory partner where the partner would be responsible for the entire testing and reimbursement process.

The next important commercial step in the United States is to get Prostatype® included in Medicare's reimbursement system, which currently has a reimbursement level of approx. 3,700 USD per test for the relevant category. The company expects to submit a Medicare application in Q3 2024, and then receive approval in Q4 2024.

The US study with Prostatype®, which includes approximately 1,200 patients with prostate cancer with a broad ethnicity coverage, is progressing significantly faster than expected. The company considers robust American study results with Prostatype® to be very important to reach comprehensive clinical usage of the test, and they will also be of great value in dialogues with American healthcare systems. The company expects to present interim data from the study with Afro-American patients in Q3, and to complete the full study in Q4.

Very strong interim results from long-term follow-up study with Prostatype® in Uppsala

Interim results from 180 of a total of approximately 500 patients in the ongoing long-term follow-up study at Akademiska University Hospital in Uppsala, Sweden, with the company's genetic test Prostatype® show excellent accuracy for Prostatype® even after 20 years of follow-up time after diagnosis. None of the analysed patients classified as low risk by Prostatype® died from their prostate cancer during 20 years of follow-up time. The interim results from the Uppsala study, together with data from the ongoing US study with Prostatype® and data from other conducted studies, will be included in the company's upcoming Medicare application in the United States with the aim to get Prostatype® approved for reimbursement in Q4 2024.

Strong positive final results from multicentre study with Prostatype® in Spain

The retrospective multicentre study in Spain with the company's gene test Prostatype®, which includes 126 patients with prostate cancer at seven hospitals and is coordinated by the Spanish National Urology Association, was completed with strong positive results. The final results show that the treatment plan could have been modified for 39% of the patients if Prostatype® had been used as a decision basis at the time of diagnosis. Prostatype® was launched in Spain in 2023, and Prostatype Genomics now

see good conditions to facilitate a broader use of the product and thus increase sales in this market.

Outcome of preferential rights issue and associated warrants of series TO3

The outcome from the rights issue that was decided on December 7, 2023 of up to approximately 47.8 MSEK before issue costs at a subscription price of 0.04 SEK was subscribed to approximately 52.3% and the company thus received approximately 25.0 MSEK before issue costs, of which 8 MSEK was used to repay bridge loans raised during the fourth quarter of 2023. The number of shares increased by 624,804,960 shares, after which a further 44,021,483 shares were issued as compensation to the guarantors.

In connection with this rights issue, a warrant in series TO3 was issued for each newly subscribed share. After the subscription period, which was April 5 – 19, it was established that 202,524,736 options and shares were subscribed at the price of 0.04 SEK, of which 800 TSEK was set off. This corresponds to a subscription rate of approx. 81.0 percent, and the company received proceeds of approximately 7.3 MSEK before issuing costs.

In January, the reduction of the share capital by 5,973,000 SEK, which was decided at the extraordinary general meeting on December 7, 2023, was carried out.

Aktiespararna sees large upside in the Prostatype Genomics share with a target price of 0.12 SEK

In a research report by Aktiespararna published on April 27, the target price for the company's share is set at 0.12 SEK per share, and the share is thus deemed to have "a large upside compared to today's levels".

In the research report, the global addressable market for the genetic test Prostatype® is estimated at 5.8 billion SEK annually, of which the United States is estimated to make up approximately 65 percent (3.8 billion SEK), and the research report assumes that the main sales revenue is expected to come from this market.

Rights issue of units of approximately 49.5 MSEK

The Board of Directors in Prostatype Genomics has, subject to approval by an extraordinary general meeting, resolved to carry out an issue of 990,811,186 units, with preferential rights for the company's existing shareholders (the "Rights Issue"). Each unit in the Rights Issue consists of five (5) shares and two (2) warrants of series TO 4 (collectively, a "Unit"). Provided that the Rights Issue is fully subscribed, the company will receive initial proceeds of approximately 49.5 MSEK before the deduction of issue costs.

The Rights Issue is covered by pre-subscriptions and guarantee commitments of 35.7 MSEK in total, corresponding to approximately 72.1 percent of the Rights Issue. Guarantor commitments are divided into so-called bottom guarantee commitments of 18.2 MSEK from Exelity AB, Buntel AB, Oliver Molse and Life Science Invest Fund 1 ApS and top guarantee commitments of 7.5 MSEK, with 7.0 MSEK coming from Life Science Invest Fund 1 ApS and 0.5 MSEK from Gemstone Capital A/S.

Additionally, a shareholder loan of a total of 3.2 MSEK will be converted within the Issue, or in a separate Directed Issue ("Directed Issue") on identical terms as the Rights Issue.

In order to secure the company's liquidity needs until the Rights Issue has been completed, the company has obtained a bridge loan of 6.5 MSEK, which will be paid back when the company receives the proceeds from the Rights Issue.

As a minimum, the company will thus receive gross proceeds of approximately 35.7 MSEK and net cash proceeds of approximately 27.5 MSEK before the repayment of the bridge loan. The total costs, including the costs of the bridge loan, are 8.2 MSEK, of which 4.4 mSEK assumes all guarantors choose cash as compensation for their respective guarantee undertakings.

The net proceeds from the issue thus cover the expected and previously communicated capital requirement to reach Medicare approval in the United States. This rights issue is the first step in a long-term financing plan where the company welcomes Life Science Invest Fund 1 ApS as both long-term investor and top guarantor in the issue.

The subscription period for the Rights Issue runs from 19 August 2024 to and including 2 September 2024.

Significant events after the end of the period

Approved issue of 49.5 MSEK

The preferential rights issue proposed by the Board of Directors on June 13, 2024 was approved by an extraordinary general meeting on July 16, 2024.



CEO Fredrik Rickman comments

During the first half of 2024, a new promising chapter in the history of Prostatype Genomics began when we entered the US market with our genetic test Prostatype®, a market with annual sales of approximately 2 billion SEK and a potential that we estimate to be at least 6 billion SEK. At the same time, a multicentre study was completed in Spain with positive results, which means that many private healthcare providers and university hospitals in the country now want to start using Prostatype® as part of their clinical practice. We now have an exciting second half of the year ahead of us, with expected inclusion in Medicare's reimbursement system (currently approx. 3,700 USD per test) in the United States in Q4 as the most important milestone.

After having established an initial organization in the United States in 2023 under the leadership of the highly qualified Steven Gaal, with experience from taking a product similar to Prostatype® to market entry, Medicare approval and significant commercial success, we have been able to achieve several milestones in this market in 2024.

By obtaining the necessary CLIA certification and other regulatory approvals, we were able to during the period launch Prostatype® in the United States as a so-called LDT test (laboratory developed test), which means that we do not need any FDA approval. We have done this in an optimal way as we have full control over the entire business in the United States, including handling reimbursement from healthcare systems, something that is otherwise often done by a partner for a significant part of the revenue for each test. By signing a flexible agreement with the company ResearchDx, we will also be able to scale up the testing operations in the United States in line with our sales growth

without having to invest in our own lab facilities.

In parallel with the above, an extensive US study with Prostatype® is being carried out with approximately 1,200 patients and a wide range of ethnicities, including Afro-Americans. This study is expected to provide us with the regionally obtained scientific basis required for the entire urology sector to feel confident in being able to use our product on a large scale. The study is also important in our dialogues with American healthcare systems. We expect interim data with Afro-American patients to be presented in Q3, and the full study to be completed in Q4.

The next step in the United States is submitting an application to Medicare to have Prostatype® included in their reimbursement system, which means that patients no longer have to pay for the test themselves. We expect to submit our application in Q3 and receive approval in Q4.



The next step in the United States is submitting an application to Medicare to have Prostatype® included in their reimbursement system, which means that patients no longer have to pay for the test themselves. We expect to submit our application in Q3 and receive approval in Q4.


Upon Medicare approval, widespread use in the United States can begin, but we are already working with leading urologists such as Professor E. David Crawford, MD, University of California to begin clinical use and ensure that our product is easily integrated into the workflow of American urologists. Having American urologists of this calibre with us right from the start says something about how strong the interest is in Prostatype® in the United States, and thus the need to be able to offer an even better decision-making basis to patients with prostate cancer.

We also made progress with our focused commercial activities in Europe during the period. Here, Spain is the most promising market. Following a completed Spanish multicentre study in the spring, we have now begun to sign agreements with private healthcare providers for the clinical use of Prostatype®. Negotiations are also ongoing with more private healthcare providers and university hospitals, where the focus is on securing budgeted financing for using the test.

It is also important to highlight the ongoing long-term study with Prostatype® in Uppsala, where interim results indicate that the test is very reliable even for predictions 20 years into the future, i.e. twice as long as we offer today. If these results hold, we will be able to offer even greater medical and financial benefits to patients, healthcare providers, and healthcare systems in the years to come.

We are now entering the second half of the year where we expect Prostatype® to be included in the Medicare reimbursement system in the United States, which would be a crucial milestone for the company. We are already preparing for the next step, which is to shift most of our resources from scientific validation and regulatory processes to marketing and sales. The proceeds from our upcoming new share issue will be used to enable us to get there, and thus finally begin to realize the significant underlying values that we have built up in the company for a long time. I would like to thank all shareholders who contributed to our financing during the period, despite a very challenging financing climate, and hope that you, like myself, will participate in the upcoming rights issue.

Fredrik Rickman
CEO Prostatype Genomics AB
Solna, 26 July 2024



Key figures

Group

TSEK	2023 July-Dec	2022 July-Dec	2023 Full year
Net sales	115	447	1,356
EBITDA	-18,437	-19,575	-37,372
Total Assets	32,272	32,067	49,222
Total Equity	13,286	26,182	24,674
Net cash-flows	-935	476	-8,793
Equity/Assets-ratio	41%	82%	50%
Number of employees EoP	6	8	6
Number of shares at the end of the period	990,811,186	119,460,007	119,460,007
Number of shares at the end of the period after full dilution	990,811,186	119,619,878	119,460,007
Average number of shares for the period	632,852,548	55,060,541	80,820,327
Earnings per share, SEK			
- Before dilution	-0.02	-0.17	-0.35
- After dilution	-0.02	-0.17	-0.35

Definition of key ratios

Operating margin

Operating profit/loss after depreciation / net sales

Equity/debt ratio

Equity / total assets

Earnings per share

Net profit/loss for the year / number of shares by period closing

Diluted earnings per share

Net profit/loss for the year / (number of shares + warrants by period closing)

Financial development

First half of 2024

Net sales and results

Net sales for the first half of 2024 amounted to 115 TSEK (447). The group is still in the initial phase of commercialization, and thus the net sales is in line with expectations.

The operation profit/loss for the company (EBIT) amounted to -19,400 TSEK (-20,514), a small improved compared to the corresponding period of the previous year. The company's costs mainly consist of research, testing, personnel and commercialization.

Earnings per share for the period amounted to -0.02 SEK (-0.17).

Investments

The investments mainly relate to our product development in and towards the United States and amount to a total of 6,526 TSEK (799).

Cash flow and liquid assets

The cash flow during the period amounted to -935 TSEK (476). The group's cash and cash at the end of the period amounted to 1,785 TSEK (11,972).

The parent company

The parent company's net sales and operating result amounted to 115 TSEK (447) and -15,148 TSEK (-17,850), respectively. The company invested -3,150 TSEK (-) in product development and financed subsidiaries with 5,949 TSEK (3,726). The net cash flow amounted to -488 TSEK (186) and cash and cash equivalents at the end of the period amounted to 1,581 TSEK (11,675).

The share

The company's share is listed on the NASDAQ First North Growth Market under the symbol PROGEN and is traded with ISIN code SE0014684569.

On 30 June 2024, the share capital amounted to 9908,112 SEK (7,167,600) distributed over 990,811,186 shares (119,460,007). All shares are issued and fully paid.

After the end of the period, it was decided at an extraordinary general meeting on 16 July 2024 to increase the share capital through a rights issue of a maximum of 990,811,186 units, corresponding to a maximum of 4,954,055,930 new shares and 1,981,622,372 warrants of series TO4. The share capital can thus increase by up to a total of 69,356,783 SEK, of which up to SEK 49,540,559 SEK from the initial rights issue.

A list of the largest shareholders can be found on the company's website (www.prostatypegenomics.com).

The balance sheet

At the end of the period, the group has intangible fixed assets of SEK 29,095 TSEK (16,669) and cash and cash equivalents of 1,785 TSEK (11,792). The group's equity amounts to 13,446 TSEK (26,182) and outstanding loans amount to 10,292 TSEK (666).

The group's intangible assets represent values ??for expenses, development work and patents regarding the company's product. Development expenses and patents are written off on a straight-line basis over 10 years.

Liquidity, financing, capital requirements

Liquidity

During the first half of the year, the company has had a strained liquidity as a result of the fact that the rights issues carried out in 2023 did not yield sufficient outcomes, while entering the US market is costly.

Financing

At the end of the period, the group has a total of 10.3 MSEK in external loan financing. In addition to a loan from Almi, this includes a 3.2 MSEK shareholder loan from board member Håkan Engström and a 6.5 MSEK bridge loan that were signed in connection with the terms of the rights issue being finalized by the board in June 2024.

After the end of the period, it was decided at an extraordinary general meeting on 16 July 2024 on a rights issue of up to approximately 49.5 MSEK with attached warrants. The rights issue, with a subscription period of 19 August 2024 through 2 September, 2024, is guaranteed to 72%, which means that the company will initially receive approximately 35.7 MSEK in cash before issue costs.

The above-mentioned shareholder loan is intended to be set off against shares in the upcoming rights issue, when the bridge loan together with the setup fee and interest must also be repaid.

Capital requirements

The group will be in need of growth financing after 2024 to continue operations according to the current business plan.

The board is actively working with various alternatives and the report is prepared based on the assumption of continued operation. In the event that financing of the capital requirement does not occur, it would indicate that the group may lack the liquidity required for the group to be able to continue its operations during the next 12 months.

Forward-looking statements

Certain statements in this report are forward-looking and actual results may differ materially. In addition to the factors discussed, other factors may have an impact on actual outcomes. Such factors include developments for customers, competitors, effects of economic and market conditions, national and international laws and regulations, tax regulations, fluctuations in exchange rates and interest rates and political risks.



Income statement

Consolidated income statement in summary

TSEK	2024 Jan-Jul	2023 Jan-Jul	2023 Full year
Net sales	115	447	1,356
Own work capitalized	1,333	614	2,372
Other operating income	65	-	59
Total income	1,514	1,061	3,787
Research and development cost	-980	-2,051	-3,225
Other external costs	-10,816	-10,148	-19,446
Staff cost	-7,896	-8,417	-18,488
Depreciation and impairment of tangible and intangible fixed assets	-963	-939	-1,875
Other operating expenses	-259	-20	-
Total operating costs	-20,914	-21,574	-43,034
Operating profit/loss (EBIT)	-19,400	-20,514	-39,247
Interest income and similar items	1	-	4
Interest expense and similar items	-827	-45	-1,540
Currency effects	561	-	-652
Profit/loss after financial items	-19,665	-20,558	-41,435
Current tax	-	-	-
Net profit/loss for the period	-19,665	-20,558	-41,435

Statement of positions

The consolidated statement of positions in summary

TSEK	2024-06-30	2023-06-30	2023-12-31
ASSETS			
Non-current intangible assets	28,962	16,528	23,180
Non-current tangible assets	53	68	60
Non-current financial assets	81	72	72
Total non-current assets	29,095	16,669	23,312
Inventory	201	293	203
Other current receivables	1,192	3,132	1,531
Subscribed but not paid-up rights issue	-	-	21,493
Cash and bank	1,785	11,972	2,682
Total current assets	3,177	15,398	25,910
Total assets	32,272	32,067	49,222
Equity and liabilities			
Share capital	9,908	7,168	7,168
Other capital	183,105	164,201	177,153
Other equity including net profit/loss for the period	-179,727	-145,187	-159,647
Total equity	13,286	26,182	24,674
Non-current liabilities	-	266	67
Current liabilities	18,986	5,619	24,482
Total liabilities	18,986	5,885	24,548
Total equity and liabilities	32,272	32,067	49,222
Pledged securities	3,612	3,610	3,612
Contingent liabilities	-	-	-

Cash flow

Consolidated cash flow in summary

TSEK	2024 Jan-Jul	2023 Jan-Jul	2023 Full year
Profit/loss after financial items	-19,665	-20,558	-41,435
Adjustments for items not included in cash flow etc.	400	889	2,474
Cash flow from operating activities before changes in working capital	-19,266	-19,669	-38,961
Change in inventory	3	-111	-21
Change in operating receivables	339	-634	980
Change in operating liabilities	-4,287	1,214	8,864
Change in working capital	-3,945	469	9,823
Cash flow from current operations	-23,211	-19,200	-29,138
Investments in intangible assets	-6,526	-724	-8,487
Investments in tangible assets	-	-75	-75
Change in financial assets	-8	-4	-4
Cash flow from investment activities	-6,534	-803	-8,566
Share issue proceeds, net	29,385	20,679	18,111
Loans raised	8,825	5,000	16,200
Loans amortized	-9,400	-5,200	-5,400
Cash flow from financing activities	28,810	20,479	28,911
Changes in cash and cash equivalents	-935	476	-8,793
Cash and cash equivalents at the beginning of the period	2,682	11,489	11,489
Translation differences cash and cash equivalents	37	8	-13
Cash and cash equivalents at the end of the period	1,785	11,972	2,682

Equity

The group's change in equity

TSEK	Share capital	Other capital/ premium reserves	Other equity including net profit/loss for the year	Total equity
Opening balance 2023-01-01	1,372	149,318	-124,539	26,151
New share issues	5,796	18,206	-	24,002
Issue expenses	-	-3,323	-	-3,323
Currency translation differences	-	-	-90	-90
Profit/loss for the period	-	-	-20,558	-20,558
Closing balance 2023-06-30	7,168	164,201	-145,187	26,182
Reduction of share capital	-	-5,973	5,973	-
Net share issues, subscribed not paid-up	-	24,992	-	24,992
Issue expenses	-	-6,067	-	-6,067
Currency translation differences	-	-	443	443
Profit/loss for the period	-	-	-20,877	-20,877
Closing balance 2023-12-31	7,168	177,153	-159,647	24,674
Opening balance 2024-01-01	7,168	177,153	-159,647	24,674
Reduction of share capital, registration	-5,973	5,973	-	-
New share issues	8,714	1,148	-	9,862
Issue expenses	-	-1,170	-	-1,170
Currency translation differences	-	-	-414	-414
Profit/loss for the period	-	-	-19,665	-19,665
Closing balance 2024-06-30	9,908	183,105	-179,727	13,286

The share capital of 9,908,112 SEK is distributed over 990,811,186 shares.

Parent company

Parent company condensed financial statements

Income statement

TSEK	2024 Jan-Jul	2023 Jan-Jul	2023 Full year
Income	115	447	1,414
Operating expenses	-14,327	-17,359	-32,384
Depreciation, amortization and impairment	-936	-939	-1,875
Operating profit/loss	-15,148	-17,850	-32,845
Financial items	282	-45	-1,714
Profit/loss after financial items	-14,865	-17,895	-34,559
Taxes	-	-	-
Net profit/loss for the period	-14,865	-17,895	-34,559

Balance sheet

TSEK	2024-06-30	2023-06-30	2023-12-31
Non-current assets	38,526	19,648	20,573
Current assets excl. cash and cash equivalents	2,434	3,437	23,489
Cash and cash equivalents	1,581	11,675	2,069
Total Assets	42,541	34,760	46,131
Equity	25,023	28,935	31,196
Non-current liabilities	-	266	67
Current liabilities	17,518	5,559	24,321
Total equity and liabilities	42,541	34,760	55,584

Cash-flow

TSEK	2024 Jan-Jul	2023 Jan-Jul	2023 Full year
Cash-flows from operating activities	-20,192	-16,488	-22,772
Cash-flows from investing activities	-9,106	-3,805	-15,559
Cash-flows from financing activities	28,810	20,479	28,911
Change in cash	-488	186	-9,420
Cash balance at the end of the period	1,581	11,675	2,069

Change in equity

TSEK	Share capital	Other restricted capital	Development fund	Share Premium	Profit/loss brought forward	Total
Opening balance 2023-01-01	1,372	-	16,710	149,318	-141,249	26,151
New share issues	5,796	-	-	18,206	-	24,002
Reduction of share capital	-	-5,973	-	-	5,973	-
Net share issues, subscribed not paid-up	-	6,248	-	18,744	-	24,992
Issue expenses	-	-	-	-9,391	-	-9,391
Change in development fund	-	-	-1,857	-	1,857	-
Profit/loss for the period	-	-	-	-	-34,559	-34,559
Closing balance 2023-12-31	7,168	275	14,853	176,878	-167,978	31,196
Reduction of share capital, registration	-5,973	5,973	-	-	-	-
New share issues	8,714	-6,248	-	7,396	-	9,862
Issue expenses	-	-	-	-1,170	-	-1,170
Profit/loss for the period	-	-	-	-	-14,865	-14,865
Closing balance 2024-06-30	9,908	-	14,853	183,105	-182,843	25,023

General information

Company information

Prostatype Genomics AB with organization number 556726-0285 is a limited company registered in Sweden, domiciled in Stockholm. The address is Gustaf III:s Boulevard, 169 73 Solna.

The company is engaged in the research and developments of medical devices and the sales of these.

Prostatype® is the result of more than fifteen years of research into the genomics of prostate cancer. The company was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market ready product Prostatype® Test System. Prostatype® is a test for diagnosis and prognosis that has been developed to provide the complementary information that is often needed for the selection of the optimal treatment strategy for each patient. The test analyzes the gene expression in cancer cells from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed. Aided by AI (Artificial Intelligence) technology, the gene test of Prostatype Genomics makes it possible to make a better prognosis and to classify the patient's illness into different risk types. In that way the company can reduce the risk of over- or under treatment, which in many cases lead to great discomfort for the patient. Prostatype® is today the only genetic test for prostate cancer that is available in kit format. The product is also very scalable in terms of volume due to the algorithm that forms the basis of the test.

All figures in the report are in thousands of Swedish kronor (TSEK) if not otherwise specified. Amounts or information in parentheses refer to the corresponding period of the previous year. Rounding differences may therefore occur.

Accounting principles

The report has been prepared in accordance with BFNAR 2012:1 Årsredovisning och koncernredovisning (K3) issued by the Swedish Accounting Standards Boards (BFN). The accounting policy for the company complies with applied accounting principles for the most recent published annual report.

Transactions with related parties

Shareholder loan

During the first half of 2023, the company has signed a loan agreement with JDS Invest AB, where board member Håkan Englund is chairman. The loan of 2 MSEK has been signed at market terms.

Consultancy fees

The company procures services for web-based solutions for P-score from SecureAppbox AB, where Håkan Englund is chairman of the board. During the year, services for 261 TSEK (209) were procured. Håkan Englund has not been involved in the procurement of these services.

Board member Mattias Prage is employed at the law firm Lindahl KB, which the company engages for advice on legal issues and company administration. During the year, Lindahl invoiced the company 422 TSEK (888).

Johan Waldhe, who has been a board member since the 2024 annual general meeting, is CEO of the communications and consulting company Honeybadger AB. During the period, services for 1,363 TSEK (-) have been procured.

Material risks and uncertainties in summary

A description of the most significant market and business related risks can be found in the annual report for 2023, as well as in the prospectus submitted and published on the company's website www.prostatypegenomics.com

Valuation of assets

The company's product, Prostatype®, is in a commercialization phase. In addition to the short-term financial risk above, there is, as with all businesses, a long-term risk that objectives will not be achieved within the time frame on which the group's forecasts are based. If the sales do not reach the set goals so that the assumed cash flows do not occur at the rate assumed by the board and company management or are alternatively postponed further in time, or if other assumptions that formed the basis of the impairment test carried out by the company management would change in a negative way, this may lead to the intangible assets being written down at a faster rate than planned.



Other information

Financial calendar

Year-end report 2024: 2025-02-13

The company's financial reports are available on prostatypegenomics.com

Review

This interim report has not been subject to review by the company's auditors.

Certified Advisor

Carnegie Investment Bank AB (publ)
+46 (0)73 856 42 65
certifiedadviser@carnegie.se

Publication

This information is such information that Prostatype Genomics AB is obliged to make public according to the EU's market abuse regulation. The information was submitted, through the contact person below, for publication on 26 July, 2024 at 8:00 a.m. CEST.

Fredrik Rickman, CEO
+46 (0)73 049 77 01
fredrik.rickman@prostatypegenomics.com

Signing of the report

The board and the CEO assure that the interim report provides a fair overview of the group's and the parent company's operations, balance and results, and describes the significant risks and uncertainty factors that the group is facing.

Solna, 26 July, 2024

Anders Lundberg
Chairman

Håkan Englund
Board member

Michael Häggman
Board member

Mattias Prage
Board member

Jörgen Dahlström
Board member

Johan Waldhe
Board member

CEO
Fredrik Rickman

Phone: +46 (0)8-20 87 00
Website: www.prostatypegenomics.com



Prostatype Genomics AB

Gustaf III:s Boulevard 34, SE-169 73 Solna

Phone: +46 (0)8-20 87 00

Website: www.prostatypegenomics.com